Research ExplorerPublicationsPlerixafor with and without chemotherapy in poor mobilizers:...

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

Standard

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. / Hübel, K; Fresen, M M; Salwender, H; Basara, N; Beier, R; Theurich, S; Christopeit, M; Bogner, C; Galm, O; Hartwig, R; Heits, F; Lordick, F; Rösler, W; Wehler, D; Zander, Axel R.; Albert, M H; Dressler, S; Ebinger, M; Frickhofen, N; Hertenstein, B; Kiehl, M; Liebler, S; von Lilienfeld-Toal, M; Weidmann, E; Weigelt, C; Lange, F; Kröger, Nicolaus.

In: BONE MARROW TRANSPL, Vol. 46, No. 8, 8, 2011, p. 1045-1052.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hübel, K, Fresen, MM, Salwender, H, Basara, N, Beier, R, Theurich, S, Christopeit, M, Bogner, C, Galm, O, Hartwig, R, Heits, F, Lordick, F, Rösler, W, Wehler, D, Zander, AR, Albert, MH, Dressler, S, Ebinger, M, Frickhofen, N, Hertenstein, B, Kiehl, M, Liebler, S, von Lilienfeld-Toal, M, Weidmann, E, Weigelt, C, Lange, F & Kröger, N 2011, 'Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.', BONE MARROW TRANSPL, vol. 46, no. 8, 8, pp. 1045-1052. <http://www.ncbi.nlm.nih.gov/pubmed/20972470?dopt=Citation>

APA

Hübel, K., Fresen, M. M., Salwender, H., Basara, N., Beier, R., Theurich, S., Christopeit, M., Bogner, C., Galm, O., Hartwig, R., Heits, F., Lordick, F., Rösler, W., Wehler, D., Zander, A. R., Albert, M. H., Dressler, S., Ebinger, M., Frickhofen, N., ... Kröger, N. (2011). Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. BONE MARROW TRANSPL, 46(8), 1045-1052. [8]. http://www.ncbi.nlm.nih.gov/pubmed/20972470?dopt=Citation

Vancouver

Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. BONE MARROW TRANSPL. 2011;46(8):1045-1052. 8.

Bibtex

@article{e571f3eb26a24a6185d274b4f9573966,
title = "Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.",
abstract = "The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 g/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/ L. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 × 10(6) CD34+ cells/kg (1.6-5.6). There was no significant difference between G-CSF application for 4 days and for a shorter period of time (P=0.157). A total of 47 patients received plerixafor plus G-CSF combined with chemotherapy yielding a median of 3.28 × 10(6) CD34+ cells/kg (0-24.79). In all, 40 of 60 patients (66.7%) proceeded to transplantation, and achieved a timely and stable engraftment. Side effects were rare and manageable. In conclusion, mobilization with plerixafor in poor mobilizers is safe and results in a sufficient stem cell harvest in the majority of patients.Bone Marrow Transplantation advance online publication, 25 October 2010; doi:10.1038/bmt.2010.249.",
author = "K H{\"u}bel and Fresen, {M M} and H Salwender and N Basara and R Beier and S Theurich and M Christopeit and C Bogner and O Galm and R Hartwig and F Heits and F Lordick and W R{\"o}sler and D Wehler and Zander, {Axel R.} and Albert, {M H} and S Dressler and M Ebinger and N Frickhofen and B Hertenstein and M Kiehl and S Liebler and {von Lilienfeld-Toal}, M and E Weidmann and C Weigelt and F Lange and Nicolaus Kr{\"o}ger",
year = "2011",
language = "Deutsch",
volume = "46",
pages = "1045--1052",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "8",

}

RIS

TY - JOUR

T1 - Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

AU - Hübel, K

AU - Fresen, M M

AU - Salwender, H

AU - Basara, N

AU - Beier, R

AU - Theurich, S

AU - Christopeit, M

AU - Bogner, C

AU - Galm, O

AU - Hartwig, R

AU - Heits, F

AU - Lordick, F

AU - Rösler, W

AU - Wehler, D

AU - Zander, Axel R.

AU - Albert, M H

AU - Dressler, S

AU - Ebinger, M

AU - Frickhofen, N

AU - Hertenstein, B

AU - Kiehl, M

AU - Liebler, S

AU - von Lilienfeld-Toal, M

AU - Weidmann, E

AU - Weigelt, C

AU - Lange, F

AU - Kröger, Nicolaus

PY - 2011

Y1 - 2011

N2 - The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 g/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/ L. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 × 10(6) CD34+ cells/kg (1.6-5.6). There was no significant difference between G-CSF application for 4 days and for a shorter period of time (P=0.157). A total of 47 patients received plerixafor plus G-CSF combined with chemotherapy yielding a median of 3.28 × 10(6) CD34+ cells/kg (0-24.79). In all, 40 of 60 patients (66.7%) proceeded to transplantation, and achieved a timely and stable engraftment. Side effects were rare and manageable. In conclusion, mobilization with plerixafor in poor mobilizers is safe and results in a sufficient stem cell harvest in the majority of patients.Bone Marrow Transplantation advance online publication, 25 October 2010; doi:10.1038/bmt.2010.249.

AB - The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 g/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/ L. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 × 10(6) CD34+ cells/kg (1.6-5.6). There was no significant difference between G-CSF application for 4 days and for a shorter period of time (P=0.157). A total of 47 patients received plerixafor plus G-CSF combined with chemotherapy yielding a median of 3.28 × 10(6) CD34+ cells/kg (0-24.79). In all, 40 of 60 patients (66.7%) proceeded to transplantation, and achieved a timely and stable engraftment. Side effects were rare and manageable. In conclusion, mobilization with plerixafor in poor mobilizers is safe and results in a sufficient stem cell harvest in the majority of patients.Bone Marrow Transplantation advance online publication, 25 October 2010; doi:10.1038/bmt.2010.249.

M3 - SCORING: Zeitschriftenaufsatz

VL - 46

SP - 1045

EP - 1052

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 8

M1 - 8

ER -